XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the Aright curved arrow G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.
Medical School, Southeast University, Nanjing, China.
Jifeng
J
Feng
Xinchen
X
Sun
Ning
N
Sun
Shukui
S
Qin
Fan
F
Li
Hongyan
H
Cheng
Baoan
B
Chen
Yuandong
Y
Cao
Jun
J
Ma
Lu
L
Cheng
Zuhong
Z
Lu
Jiazhong
J
Ji
Yingfeng
Y
Zhou
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004268:DNA-Binding Proteins / Q000235:genetics; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D004720:Endonucleases / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D016015:Logistic Models; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage; D020641:Polymorphism, Single Nucleotide; D043823:Taxoids / Q000008:administration & dosage; D014157:Transcription Factors / Q000235:genetics; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D051760:Xeroderma Pigmentosum Group A Protein / Q000235:genetics*; D000093542:Gemcitabine; D000099250:DNA Excision Repair Protein ERCC-5
D016190:Carboplatin; D002945:Cisplatin; D004268:DNA-Binding Proteins; D003841:Deoxycytidine; D000077143:Docetaxel; D004720:Endonucleases; D009687:Nuclear Proteins; D017239:Paclitaxel; D043823:Taxoids; D014157:Transcription Factors; D014747:Vinblastine; D000077235:Vinorelbine; D051760:Xeroderma Pigmentosum Group A Protein; D000093542:Gemcitabine; D000099250:DNA Excision Repair Protein ERCC-5; C497314:XPA protein, human